NAD⁺-related Peptides
Peptide strategies converging on NAD⁺ biology and sirtuin signalling.
- Targets central to NAD⁺-dependent ageing biology (sirtuins, PARP, CD38)
- Includes peptide adjuncts that influence NAMPT-mediated salvage of NAD⁺
- Mitochondrially-targeted peptides that preserve NAD⁺/NADH balance under stress
- Distinct from small-molecule NMN/NR — covered here for context only
Overview
This page covers a small and heterogeneous research category: peptides and peptide-conjugate strategies that intersect with NAD⁺ biology — the cofactor at the centre of sirtuin signalling, PARP-mediated DNA damage response, and mitochondrial electron transport. The category includes peptides that modulate the NAD⁺ salvage pathway, peptide carriers that deliver NMN or other NAD⁺ precursors, and mitochondrially-targeted peptides whose net effect is preservation of cellular NAD⁺/NADH ratios under stress.
NAD⁺ itself is a small-molecule cofactor, not a peptide. The most-studied small-molecule NAD⁺ precursors — nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) — are nucleoside derivatives and fall outside the scope of this site. They are mentioned here only for context. The peptide entries below intersect with NAD⁺ biology through indirect mechanisms.
Because this category is heterogeneous, the structure of this page differs from the others on the site: it summarises the published peptide-side approaches to NAD⁺ modulation rather than presenting a single named compound. As with all research peptides, the entries below are research tools and have no licensed therapeutic use in the United Kingdom.
Mechanism of action
Three intersecting peptide approaches exist in the published literature. The first is direct sirtuin modulation: short peptides have been designed as substrate mimetics or allosteric modulators of SIRT1, SIRT3 and SIRT6, although this work is largely preclinical and has not produced clinical-stage candidates. SIRT3-modulating peptides in particular are of interest for mitochondrial energetics.
The second is preservation of NAD⁺ levels through mitochondrial-membrane stabilisation. Peptides such as SS-31 (covered separately on this site) restore cristae structure and indirectly preserve NAD⁺/NADH balance in aged or stressed mitochondria. The effect is downstream of architecture preservation rather than direct enzymatic modulation, but the net consequence on NAD⁺-dependent biology is significant.
The third is conjugate-delivery strategies: peptide carriers used to improve cellular or tissue-selective delivery of small-molecule NAD⁺ precursors. This is an active research area but has not yet produced widely-available research-grade conjugate products.
Across all three approaches the underlying ageing-biology rationale is the same: NAD⁺ levels fall with age, sirtuin activity declines correspondingly, and restoration of NAD⁺ availability is hypothesised to recover sirtuin-dependent metabolic and DNA-repair programmes. Whether peptide-based strategies offer advantages over direct precursor supplementation is an open research question.
Research history
Peptide-based NAD⁺ modulation has been a niche thread within the broader NAD⁺ biology field. Major research milestones have been small-molecule rather than peptide: the work of Imai and Guarente identifying sirtuins as NAD⁺-dependent deacetylases (1999–2000), the Sinclair group's characterisation of NMN and NR as precursors capable of restoring tissue NAD⁺ (2013–2018), and clinical trials of NMN supplementation in human cohorts (2019 onward).
Peptide-side contributions have included synthesis of sirtuin-substrate mimetic peptides for structural studies, design of cell-penetrating peptide carriers for NAD⁺ precursor delivery, and characterisation of mitochondrial peptide effects on NAD⁺ pools. These threads remain preclinical.
Summarised studies
Mitochondrial-targeted peptide preservation of NAD+/NADH balance in aged muscle
Campbell MD, Duan J, Samuelson AT, et al.
SS-31 treatment preserved mitochondrial NAD⁺/NADH ratio and restored SIRT3-target acetylation patterns in aged muscle.
Sirtuin substrate-mimetic peptides as structural probes
Hawse WF, Wolberger C
Structural characterisation of sirtuin–substrate peptide interactions provided basis for design of allosteric modulators.
NAD⁺ precursor pharmacology — context for peptide adjunct research
Rajman L, Chwalek K, Sinclair DA
Synthesis of NMN and NR pharmacology in mouse and human; framing of NAD⁺ as a central node in ageing biology.
Cell-penetrating peptide conjugates as carriers for NAD⁺ precursor delivery
Various — early conjugate development reports
Demonstration that peptide-conjugate strategies can improve tissue selectivity of NAD⁺ precursor delivery; preclinical proof-of-concept only.
Safety profile
Because this category covers multiple distinct compound classes, safety considerations vary. The most clinically-advanced compound that intersects with NAD⁺ biology — SS-31/elamipretide — has the safety profile summarised on its dedicated page. Direct sirtuin-modulating peptides and peptide–small-molecule conjugates are at earlier preclinical stages and have not been characterised in human safety datasets.
Standard considerations for unlicensed research peptides apply across the category. Subjects with active malignancy or on chemotherapeutic regimens that interact with NAD⁺-dependent DNA repair pathways would require specialist input for any research protocol.
UK regulatory status
No peptide compound currently positioned within the NAD⁺ biology research space holds UK marketing authorisation. The compounds discussed here are research-grade material for laboratory and preclinical use only.
NMN and NR small-molecule precursors are supplied as food supplements in some jurisdictions but their regulatory status in the UK has been the subject of revision under the Novel Foods regulations. NMN/NR small molecules are outside the scope of this peptide-focused site.
Frequently asked questions
Is NAD⁺ itself a peptide?
No. NAD⁺ (nicotinamide adenine dinucleotide) is a small-molecule cofactor, not a peptide. This page covers peptide-class compounds that intersect with NAD⁺ biology, not NAD⁺ itself or its small-molecule precursors NMN and NR.
What is the relationship between peptides and sirtuins?
Sirtuins are NAD⁺-dependent deacetylases that play a central role in ageing biology. Peptide research has intersected with sirtuin biology through (1) substrate-mimetic peptides used as structural probes, (2) mitochondrial peptides that preserve NAD⁺/NADH balance and indirectly support SIRT3 function, and (3) peptide-conjugate delivery strategies for NAD⁺ precursors.
Is NMN or NR a peptide?
No. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are nucleoside-derivative small molecules. They are supplemented as NAD⁺ precursors but fall outside the peptide category covered by this site.
Why is NAD⁺ relevant to longevity?
NAD⁺ levels decline with age across human tissues. The cofactor is essential for sirtuin activity, PARP-mediated DNA repair, and mitochondrial electron transport. Restoration of NAD⁺ availability is a major research direction in longevity biology.
Are there any approved NAD⁺-related peptide medicines?
No. No peptide-class compound positioned within the NAD⁺ biology space holds UK or EMA marketing authorisation. All such compounds are research-grade.
Related peptides
Adjacent compounds in the longevity research literature with overlapping mechanisms or shared research history.
A mitochondrially-targeted aromatic-cationic tetrapeptide that binds inner-mitochondrial-membrane cardiolipin and stabilises mitochondrial cristae structure, studied in cardiac, renal and skeletal-muscle ageing.
A 16-amino-acid mitochondrially-derived peptide encoded within the mitochondrial 12S rRNA gene; functions as an exercise-mimetic regulator of insulin sensitivity, AMPK signalling and metabolic homeostasis.
A 24-amino-acid mitochondrially-derived peptide encoded within the 16S rRNA gene, studied for cytoprotective, metabolic and neuroprotective signalling that declines with age.
References
- Rajman L et al., Cell Metab 2018 — NAD⁺ precursor pharmacology
- Imai SI, Guarente L, Nature 2000 — sirtuin identification (historical)
See also our editorial coverage at PeptideAuthority.co.uk for related research dossiers.